Gyroscope Therapeutics Raises $148M in Series C Financing

27 Mar, 2021

Gyroscope Therapeutics Raises $148M in Series C Financing
Photo by Jonathan Francisca on Unsplash

– Gyroscope Therapeutics from London develops a gene therapy for various eye diseases.
– The company raised $148m in Series C funding.
– The round was led by Forbion’s Growth Opportunities Fund and includes Sofinnova Investments, funds and accounts advised by T. Rowe Price Associates, Inc., Tetragon Financial Group Limited, an undisclosed healthcare focused fund, Fosun Pharma, Cambridge Innovation Capital and founding investor Syncona.
– The company also announced the appointments of Wouter Joustra, General Partner, Forbion and Maha Katabi, General Partner, Sofinnova to the Gyroscope Board of Directors.

Biotechnology Europe Health Care Therapeutics
Crunchbase icon

Content report

The following text will be sent to our editors: